(3S)-1-(2-氨基乙基)-3-吡咯烷醇 | 540787-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (3S)-1-(2-氨基乙基)-3-吡咯烷醇
• 中文别名: (3S)-1-(2-氨乙基)-3-吡咯烷醇
• 英文名称: 1-(2-aminoethyl)-3-(S)-hydroxy-pyrrolidine
• 英文别名: (S)-1-(2-aminoethyl)pyrrolidin-3-ol；N-(2-aminoethyl)-3-(S)-hydroxy-pyrrolidine；2-[3-(S)-hydroxy-1-pyrrolidinyl]ethylamine；(3S)-1-(2-aminoethyl)pyrrolidin-3-ol
• CAS: 540787-75-5
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: ZNLCTCNYKCENHP-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3S)-1-(2-氨基乙基)-3-吡咯烷醇 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成
  参考文献：
  名称：

  Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists

  摘要：

  Kappa opioid receptor (KOR) is an important mediator of pain signaling and it is targeted for the treatment of various pains. Pharmacophore based mining of databases led to the identification of 2-aminobenzimidazole derivative as KOR agonists with selectivity over the other opioid receptors DOR and MOR. A short SAR exploration with the objective of identifying more polar and hence less brain penetrant agonists is described herewith. Modeling studies of the recently published structures of KOR, DOR and MOR are used to explain the receptor selectivity. The synthesis, biological evaluation and SAR of novel benzimidazole derivatives as KOR agonists are described. The in vivo proof of principle for anti-nociceptive effect with a lead compound from this series is exemplified. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.064

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY
  申请人：Yamagishi Tatsuya

  公开号：US20110275628A1

  公开（公告）日：2011-11-10

  Disclosed is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a selective antagonist of a 5-HT 2B receptor. The compound and salt are useful for treatment or prevention of various diseases and conditions associated with a 5-HT 2B receptor.

  揭示的是由通式（I）表示的化合物或其药用可接受盐，其作为5-HT2B受体的选择性拮抗剂是有用的。该化合物和盐可用于治疗或预防与5-HT2B受体相关的各种疾病和症状。
• [EN] BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] BIS-PYRIDYLPYRIDONES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE DE MELANO-CONCENTRATION
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010141539A1

  公开（公告）日：2010-12-09

  The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1 ), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.

  这项发明提供了新型的双吡啶基吡啉酮，它们是黑素浓缩激素受体1（MCHR1）的拮抗剂，包含它们的药物组合物，它们的制备方法，以及它们在治疗和治疗肥胖和糖尿病中的用途。
• [EN] TETRAHYDRO-1 H-PYRAZINO[2,1 -AJISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS TÉTRAHYDRO-1H-PYRAZINO[2,1-AJISOINDOLYLQUINOLINE POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019233941A1

  公开（公告）日：2019-12-12

  The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的化合物，其中R1至R6，m和n如本文所述，以及其药用可接受的盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• [EN] N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY<br/>[FR] DERIVES DU N-ARYL-N'-ARYLCYCLOALKYL-UREE, ANTAGONISTES DE L'HORMONE MCH, TRAITANT L'OBESITE
  申请人：SCHERING CORP

  公开号：WO2003047568A1

  公开（公告）日：2003-06-12

  The present invention discloses compounds of the formula I which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

  本发明揭示了式I的化合物，它们是黑色素浓聚激素（MCH）的新型拮抗剂，以及制备这些化合物的方法。在另一实施例中，本发明揭示了包含这些MCH拮抗剂的药物组合物，以及使用它们治疗肥胖症、代谢紊乱、食欲紊乱（如暴食症）和糖尿病的方法。